Rnordeprenyl

Rnordeprenyl

SCHEMBL2477570

C#CCN[C@H](C)Cc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
TSHR P16473 1/20 1.00
SLC6A4 P31645 2/20 0.65
SIGMAR1 Q99720 12/20 0.64
TAAR1 Q96RJ0 2/20 0.57
SLC18A2 Q05940 1/20 0.57
LMNA P02545 1/20 0.56
ADRB2 P07550 1/20 0.54
ADRB1 P08588 1/20 0.54
HTR1A P08908 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
DRD2 P14416 1/20 0.54
ADRA2B P18089 1/20 0.54
ADRA2C P18825 1/20 0.54
CNR1 P21554 1/20 0.54
SLC6A2 P23975 1/20 0.54
HTR2A P28223 1/20 0.54
MC4R P32245 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Desmethylselegiline SCHEMBL4543249 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6TSHRSLC6A4
Rnordeprenyl SCHEMBL12171086 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6TSHRSLC6A4
Desmethylselegiline SCHEMBL27813529 0.98 CYP1A2 (0.96) CYP1A2CYP3A4CYP2D6TSHRSLC6A4
Rnordeprenyl SCHEMBL29015119 0.98 CYP1A2 (0.96) CYP1A2CYP3A4CYP2D6TSHRSLC6A4
Rnordeprenyl SCHEMBL2473190 0.98 CYP1A2 (0.96) CYP1A2CYP3A4CYP2D6TSHRSLC6A4
Desmethylselegiline SCHEMBL27813455 0.96 CYP1A2 (0.93) CYP1A2CYP3A4CYP2D6TSHRSLC6A4
SCHEMBL16335536 0.81 CYP1A2 (0.68) CYP1A2CYP3A4CYP2D6TSHRSLC6A4
SCHEMBL29059547 0.79 SIGMAR1 (0.81) CYP1A2CYP3A4CYP2D6TSHRSLC6A4
SCHEMBL18756829 0.79 CYP1A2 (0.65) CYP1A2CYP3A4CYP2D6TSHRSLC6A4
SCHEMBL7031931 0.78 CYP1A2 (0.64) CYP1A2CYP3A4CYP2D6TSHRSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110642721-B Preparation method of selegiline hydrochloride 安徽贝克生物制药有限公司 2022-09-30 CN disclosed
CN-110668951-B Synthesis process of selegiline hydrochloride 安徽贝克生物制药有限公司 2022-09-30 CN disclosed
CN-110668951-A Synthesis process of selegiline hydrochloride 安徽贝克生物制药有限公司 2020-01-10 CN disclosed
CN-110642721-A Preparation method of selegiline hydrochloride 安徽贝克生物制药有限公司 2020-01-03 CN disclosed
US-10266506-B2 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PIRAMAL IMAGING SA (CH) 2019-04-23 US disclosed
US-20180022719-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PIRAMAL IMAGING SA (CH) 2018-01-25 US disclosed
US-20180022719-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PIRAMAL IMAGING SA (CH) 2018-01-25 US disclosed
EP-2388245-B1 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PIRAMAL IMAGING SA (CH) 2017-07-12 EP disclosed
EP-2388245-B1 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PIRAMAL IMAGING SA (CH) 2017-07-12 EP disclosed
US-9682944-B2 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PIRAMAL IMAGING SA (CH) 2017-06-20 US disclosed
US-20090191129-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS Lantheus Biosciences Ltd. (GB) 2009-07-30 US disclosed
US-20090191129-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS Lantheus Biosciences Ltd. (GB) 2009-07-30 US disclosed
EP-2053033-A1 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors Bayer Schering Pharma AG (DE) 2009-04-29 EP disclosed
US-20090048229-A1 Methods for promoting wakefulness COLUCID PHARMACEUTICALS, INC. 2009-02-19 US disclosed
US-20090048229-A1 Methods for promoting wakefulness COLUCID PHARMACEUTICALS, INC. 2009-02-19 US disclosed
WO-2009011901-A2 METHODS FOR PROMOTING WAKEFULNESS COLUCID PHARMACEUTICALS, INC. (US) 2009-01-22 WO disclosed
US-20070275959-A1 Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents SENTION, INC. 2007-11-29 US disclosed
US-20070275959-A1 Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents SENTION, INC. 2007-11-29 US disclosed
US-20070078172-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2007-04-05 US disclosed
US-20070078172-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022719-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PMP22, MEN1, VHL CYP1A2 4196/4885CYP3A4 4602/4885CYP2D6 4401/4885
US-10266506-B2 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors PMP22, MEN1, VHL CYP1A2 4196/4885CYP3A4 4602/4885CYP2D6 4401/4885
US-20070078172-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY MAOB, MAOA, GPR119 CYP1A2 184/4885CYP3A4 805/4885CYP2D6 713/4885
US-20070275959-A1 Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents ACHE, BCHE, CHAT CYP1A2 309/4885CYP3A4 232/4885CYP2D6 382/4885
US-20090048229-A1 Methods for promoting wakefulness HCRTR2, HCRTR1, CHAT CYP1A2 2828/4885CYP3A4 1913/4885CYP2D6 3030/4885
US-20090191129-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PMP22, MEN1, VHL CYP1A2 4196/4885CYP3A4 4602/4885CYP2D6 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.